Details for Patent: 10,238,644
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 10,238,644 protect, and when does it expire?
Patent 10,238,644 protects ZYCLARA and is included in one NDA.
This patent has thirty-five patent family members in thirty countries.
Summary for Patent: 10,238,644
| Title: | 2.times.2.times.2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod |
| Abstract: | Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara.RTM. 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration ("FDA"), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration ("FDA") for Aldara.RTM. 5% imiquimod cream to treat actinic keratosis are also disclosed and described. |
| Inventor(s): | Nordsiek; Michael T. (Wayne, PA), Levy; Sharon F. (Philadelphia, PA), Lee; James Hurn-Joung (Devon, PA), Kulp; James H. (West Chester, PA), Balaji; Kodumudi S. (Lansdale, PA), Meng; Tze-Chiang (Lino Lakes, MN), Wu; Jason J. (Wayne, PA), Bahm; Valyn S. (Phoenixville, PA), Babilon; Robert (Boyertown, PA) |
| Assignee: | Medicis Pharmaceutical Corporation (Bridgewater, NJ) |
| Application Number: | 15/187,751 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 10,238,644
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch | ZYCLARA | imiquimod | CREAM;TOPICAL | 022483-001 | Mar 25, 2010 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF ACTINIC KERATOSIS | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,238,644
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 074802 | ⤷ Try a Trial | |||
| Australia | 2009335943 | ⤷ Try a Trial | |||
| Brazil | PI0923164 | ⤷ Try a Trial | |||
| Canada | 2649893 | ⤷ Try a Trial | |||
| Canada | 2709732 | ⤷ Try a Trial | |||
| Chile | 2009002183 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
